Form 4: Akero Therapeutics CEO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Akero Therapeutics CEO Andrew Cheng sold 1,969 shares of common stock on March 13, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.
Summary
- On March 13, 2024, Andrew Cheng, the President and CEO of Akero Therapeutics, Inc., sold 1,969 shares of common stock.
- The sale was executed at a price of $28.33 per share.
- This transaction was conducted to cover tax withholding obligations associated with the vesting of restricted stock units.
- Following the transaction, Cheng directly owns 589,447 shares of Akero Therapeutics common stock.
- The sale was automatic under the issuer's 'sell-to-cover' policy and not at the discretion of the reporting person.
Sentiment
Score: 6
Explanation: The document reflects a routine transaction (sale of shares to cover taxes) and doesn't inherently indicate positive or negative sentiment. It's a neutral event in the context of executive compensation and standard company policy.
Industry Context
Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives and do not necessarily indicate a negative outlook on the company's future.
Key Dates
| Date | Description |
|---|---|
| 03/13/2024 | Date of stock sale transaction |
| 03/15/2024 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.